14505-27-2

Basic information

• Product Name: Methyl-α-cyano-β-methyl-β-phenylacrylat
• Synonyms: Methyl-α-cyano-β-methyl-β-phenylacrylat
• CAS NO: 14505-27-2
• Molecular Weight: 201.225
• Mol File: 14505-27-2.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: Methyl-α-cyano-β-methyl-β-phenylacrylat(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl-α-cyano-β-methyl-β-phenylacrylat(14505-27-2)
• EPA Substance Registry System: Methyl-α-cyano-β-methyl-β-phenylacrylat(14505-27-2)

Safety Data

• Hazardous Substances Data: 14505-27-2(Hazardous Substances Data)

Upstream product

• 2373-51-5 chloro-methylsulfanyl-methane 
• 29840-32-2 3-Benzyl-2,3-dicyan-buttersaeure-methylester 
• 98-86-2 acetophenone 
• 105-56-6 ethyl 2-cyanoacetate 
• 105-34-0 methyl 2-cyanoacetate 

Downstream Products

• 89991-60-6 methyl 2-cyano-3-phenylbutyrate 
• 95240-86-1 (Z)-2-Cyano-5,5-bis-methylsulfanyl-3-phenyl-penta-2,4-dienoic acid methyl ester 
• 79250-77-4 (E)-2-Cyano-5,5-bis-methylsulfanyl-3-phenyl-penta-2,4-dienoic acid methyl ester 
• 1610505-58-2 C₁₆H₁₂N₄S₂ 
• 852934-01-1 4-chloro-5-phenyl-2-thiophen-2-yl-thieno[2,3-d]pyrimidine 
• 852933-90-5 C₁₆H₁₀N₂OS₂ 
• 67171-55-5 2-amino-4-phenylthiophene-3-carboxylic acid methyl ester 
• 1622230-17-4 C₁₉H₁₄N₂O₂S 
• 1622230-18-5 C₂₀H₁₇N₃OS 
• 1622230-19-6 C₁₈H₁₃N₃OS 
• 949527-16-6 4-chloro-2-(-4-methoxy-phenyl)-5-phenyl-thieno[2,3-d]pyrimidine 
• 949527-24-6 [4-(4-chloro-5-phenyl-thieno[2,3-d]pyrimidin-2-yl)-phenyl]-dimethyl-amine 
• 949527-25-7 4-(4-chloro-5-phenyl-thieno[2,3-d]pyrimidin-2-yl)-phenylamine 
• 1622230-22-1 C₁₉H₁₆N₄OS 

Relevant articles and documents

Synthesis and biological evaluation of novel thieno[2,3-d]pyrimidine-based FLT3 inhibitors as anti-leukemic agents

The most common mutations in acute myeloid leukemia (AML) are those that cause the activation of FMS-like tyrosine kinase 3 (FLT3). Therefore, FLT3 is regarded as a potential target for the treatment of AML. A novel series of thieno[2,3-d]pyrimidine-based analogs was designed and synthesized as FLT3 inhibitors. All synthesized compounds were assayed for the tyrosine kinase activity of FLT3 and growth inhibitory activity in four human leukemia cell lines (THP1, MV4-11, K562, and HL-60). Among these compounds, compound 17a, which possesses relatively short and simple substituents at the C6 position of thieno[2,3-d]pyrimidine, emerged as the most promising anti-leukemic agent. Compound 17a exhibited potent inhibition of FLT3-positive leukemic cell growth and of the FLT3 D835Y kinase; such inhibition is required for the successful treatment of AML. The data supports the further investigation of this class of compounds as potential anti-leukemic agents.

Synthesis and biological evaluation of novel thieno[2,3-d[pyrimidine-based FLT3 inhibitors as anti-leukemic agents

The most common mutations in acute myeloid leukemia (AML) are those that cause the activation of FMS-like tyrosine kinase 3 (FLT3). Therefore, FLT3 is regarded as a potential target for the treatment of AML. A novel series of thieno[2,3-d]pyrimidine-based analogs was designed and synthesized as FLT3 inhibitors. All synthesized compounds were assayed for the tyrosine kinase activity of FLT3 and growth inhibitory activity in four human leukemia cell lines (THP1, MV4-11, K562, and HL-60). Among these compounds, compound 17a, which possesses relatively short and simple substituents at the C6 position of thieno[2,3-d]pyrimidine, emerged as the most promising anti-leukemic agent. Compound 17a exhibited potent inhibition of FLT3-positive leukemic cell growth and of the FLT3 D835Y kinase; such inhibition is required for the successful treatment of AML. The data supports the further investigation of this class of compounds as potential anti-leukemic agents.